Trial Profile
Phase 2 Trial of SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 20 Apr 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as the project was never initiated and no participants were enrolled.
- 12 Jan 2018 Planned initiation date changed from 1 Oct 2017 to 1 Mar 2018.
- 28 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Oct 2017.